cvtoken.vip

A single RNA-based therapeutics approach against multiple types of RNA viruses

The high frequency of RNA virus mutations and outbreaks of emerging RNA viral infections are challenging public health issues. Developing a drug that can overcome viral mutations with broad-spectrum antiviral ...

A single RNA-based therapeutics against multiple types of RNA viruses
The proposed mechanism for MOM-ENDOG-mediated anti-virus activity. Credit: Nature Communications (2026). DOI: 10.1038/s41467-026-73487-1

The high frequency of RNA virus mutations and outbreaks of emerging RNA viral infections are challenging public health issues. Developing a drug that can overcome viral mutations with broad-spectrum antiviral activity is an unmet need.

Scientists at National Taiwan University have observed RNA synthesis by RNA viruses at mitochondria/endoplasmic reticulum (Mito/ER) spheres in infected cells, accompanied by the leakage of a mitochondrial nuclease, ENDOG, into the cytosol.

ENDOG released from mitochondria can degrade viral RNAs as an antiviral factor. However, the released ENDOG can also translocate to nuclei and cause nuclear DNA damage.

Researchers then engineered an ENDOG anchored to the mitochondrial surface, namely MOM-ENDOG, whose expression efficiently degrades viral RNA transcripts synthesized at mitochondrial sites without causing nuclear DNA damage. Delivery of modified mRNA encoding wild-type, but not catalytic-dead, MOM-ENDOG markedly suppresses the propagation of VSV, influenza, dengue and Zika viruses.

"This modified mRNA encoding mitochondrial site-specific viral RNA degrader is a broad-spectrum antiviral agent and its mode of action would not be affected by the viral mutations," said Zee-Fen Chang, chair professor at the Center of Nucleic Acid Medicine, National Taiwan University College of Medicine and corresponding author of the study published in Nature Communications.

Publication details

Chih-Wei Chen et al, An engineered viral RNA degrader on mitochondrial surface that mitigates RNA virus infection, Nature Communications (2026). DOI: 10.1038/s41467-026-73487-1

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: A single RNA-based therapeutics approach against multiple types of RNA viruses (2026, July 31) retrieved 31 July 2026 from https://phys.org/news/2026-07-rna-based-therapeutics-approach-multiple.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.